Paravasthu Mukund - Nov 2, 2024 Form 4 Insider Report for NovoCure Ltd (NVCR)

Role
Chief Operating Officer
Signature
Ovie Onobrakpeya, as attorney in fact for Paravasthu, Mukund
Stock symbol
NVCR
Transactions as of
Nov 2, 2024
Transactions value $
$756,102
Form type
4
Date filed
11/6/2024, 04:27 PM
Previous filing
Nov 4, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NVCR Ordinary Shares Sale -$734 -44 -1.26% $16.69 3.46K Nov 2, 2024 Direct F1
transaction NVCR Ordinary Shares Award $0 +30.1K +871.29% $0.00 33.6K Nov 4, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NVCR Stock Option (Right to Buy) Award $757K +45.6K $16.59 45.6K Nov 4, 2024 Ordinary Shares 45.6K $16.59 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F2 Represents restricted share units that are scheduled to vest in equal parts on November 4, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates.
F3 Options to buy 45,620 ordinary shares will vest in equal installments on each of November 4, 2025, 2026, 2027 and 2028, subject to the reporting person's continued employment through such dates.